Rigrodsky & Long, P.A. Investigates TomoTherapy Incorporated Buyout - TOMO

  • Do you own TomoTherapy Incorporated common stock?
  • Did you purchase your shares prior to March 7, 2011?
  • Do you feel the Company's sale to Accuray is unfair?
  • Do you want to discuss your rights?

If the answer to these questions is "yes," please contact the deal lawyers at Rigrodsky & Long, P.A. ("R & L") today to schedule a FREE consultation. Just call us, or fill out our contact form so that we can call at your convenience. Your consultation will not create any obligation to use our services at any time.

Contact R & L today to be sure your best interests are being protected.

R & L is national law firm with decades of combined legal experience. R & L is investigating potential claims against the board of directors of TomoTherapy Incorporated concerning possible breaches of fiduciary duty and other violations of law related to the Company’s entry into an agreement to be acquired by Accuray in a transaction with a  total value of approximately $277 million.

Click here to read the full press release.

Rigrodsky & Long, P.A. Investigates TomoTherapy Incorporated Buyout - TOMO

Rigrodsky & Long, P.A. announces that it is investigating potential claims against the board of directors of TomoTherapy Incorporated (“TomoTherapy” or the “Company”) (Nasdaq: TOMO) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s entry into an agreement to be acquired by Accuray (Nasdaq: ARAY) in a transaction with a  total value of approximately $277 million.

Under the proposed agreement, TomoTherapy shareholders will receive $3.15 in cash and 0.1648 shares of Accuray common stock for each share of TomoTherapy common stock they own.  Based on the closing price of Accuray’s common stock on March 4, 2011, the stock component of the consideration is valued at $1.65 per share.

The investigation concerns whether TomoTherapy’s board of directors failed to adequately shop the Company and obtain the best price possible for TomoTherapy’s shareholders or whether they put their interests above of those of the Company’s shareholders before entering into the agreement with Accuray.  Indeed, according to Yahoo! Finance, at least one analyst has set a price target of $5.00 per share for TomoTherapy stock.

If you own the common stock of TomoTherapy and purchased your shares before March 7, 2011, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky, Esquire or Noah R. Wortman, Case Development Director, of Rigrodsky & Long, P.A., 919 N. Market Street, Suite 980, Wilmington, Delaware, by telephone at (888) 969-4242, or by e-mail to info@rigrodskylong.com.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.

R & L, with offices in Delaware and New York, litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.

Learn more about R&L:  Visit Our Website |  Our Firm  |  Our Practice Areas  |  FAQ's

Fill out the form below or call us toll-free at 888-969-4242, for a FREE no-obligation consultation.